11,165
Total Claims
$2.1M
Drug Cost
605
Beneficiaries
$3,463
Cost/Patient
Peer Comparison vs. 110,156 Internal Medicine providers
+145%
Cost per patient vs peers
$3,463 vs $1,411 avg
+93%
Brand preference vs peers
20.5% vs 10.6% avg
Brand vs Generic
80% generic
Brand: 2,260 claims · $1.8M
Generic: 8,778 claims · $309K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Icosapent Ethyl | 651 | $509K |
| Dapagliflozin Propanediol | 221 | $297K |
| Empagliflozin | 161 | $189K |
| Sitagliptin Phosphate | 65 | $75K |
| Semaglutide | 30 | $68K |
| Apixaban | 53 | $61K |
| Semaglutide | 55 | $60K |
| Rivaroxaban | 45 | $42K |
| Tenofovir Alafenamide | 22 | $41K |
| Dulaglutide | 20 | $38K |
| Linagliptin | 24 | $35K |
| Icosapent Ethyl | 61 | $34K |
| Raloxifene Hcl | 259 | $31K |
| Rsv Vacc, Pref A And Pref B/Pf | 96 | $29K |
| Diclofenac Epolamine | 42 | $26K |
Prescribing Profile
Patient Profile
74
Avg Age
58%
Female
1.13
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data